Centene: The Turnaround Has More Room To Run (NYSE:CNC)

seekingalpha.com · 2026-10-15

Centene Corp. raised full-year adjusted EPS guidance to over $4.80, driven by improved Marketplace and Medicare Part D margins. Read why CNC stock is a buy.

TickrTrends take: Centene operates in the Healthcare sector and is currently assessed as overvalued according to TickrTrends valuation metrics. The headline suggests ongoing operational improvements at the company, which creates a potential disconnect between market performance narratives and the current valuation assessment that indicates prices may not reflect fundamental value. Investors focused on valuation should monitor whether continued turnaround execution can justify the existing price level or whether the overvalued designation signals limited upside from current levels.

Read the full story at seekingalpha.com →